Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.48 |
| ▸ | TACR3 | P29371 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.42 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16729219 | 1.00 | CYP3A4 (0.53) | CYP3A4ALDH1A1CYP19A1TACR3HCAR2 | |
| SCHEMBL12199933 | 0.90 | CYP3A4 (0.58) | CYP3A4ALDH1A1CYP19A1KMT2APABPC1 | |
| SCHEMBL18759651 | 0.88 | CYP3A4 (0.53) | CYP3A4ALDH1A1CYP19A1HCAR2KMT2A | |
| SCHEMBL24931236 | 0.85 | CYP3A4 (0.50) | CYP3A4ALDH1A1CYP19A1HCAR2TSHR | |
| SCHEMBL6250864 | 0.85 | CYP3A4 (0.50) | CYP3A4ALDH1A1CYP19A1HCAR2TSHR | |
| SCHEMBL4407732 | 0.85 | CYP3A4 (0.50) | CYP3A4ALDH1A1CYP19A1HCAR2TSHR | |
| Hydrochloric Acid SCHEMBL6250414 | 0.83 | CYP3A4 (0.49) | CYP3A4ALDH1A1CYP19A1HCAR2TSHR | |
| Hydrochloric Acid SCHEMBL6248395 | 0.83 | CYP3A4 (0.49) | CYP3A4ALDH1A1CYP19A1HCAR2TSHR | |
| SCHEMBL9094896 | 0.82 | CYP1A2 (0.46) | CYP3A4ALDH1A1TACR3HCAR2KMT2A | |
| SCHEMBL31060300 | 0.82 | CYP1A2 (0.46) | CYP3A4ALDH1A1TACR3HCAR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023069548-A1 | MALODOR-COUNTERACTING COMPOUNDS, COMPOSITIONS, AND USES THEREOF | INTERNATIONAL FLAVORS AND FRAGRANCES INC. (US) | 2023-04-27 | — | — | WO | claimed |
| JP-1222078-A | — | — | None | — | — | JP | disclosed |
| US-11062794-B2 | Olfactory signature and odorant mixture having the same | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2021-07-13 | — | — | US | disclosed |
| US-20180253534-A1 | OLFACTORY SIGNATURE AND ODORANT MIXTURE HAVING THE SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-09-06 | — | — | US | disclosed |
| US-9959392-B2 | Olfactory signature and odorant mixture having the same | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-05-01 | — | — | US | disclosed |
| US-20140221269-A1 | OLFACTORY SIGNATURE AND ODORANT MIXTURE HAVING THE SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2014-08-07 | — | — | US | disclosed |
| US-8642576-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-02-04 | — | — | US | disclosed |
| WO-2013035070-A1 | OLFACTORY SIGNATURE AND ODORANT MIXTURE HAVING THE SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2013-03-14 | — | — | WO | disclosed |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-20 | — | — | US | disclosed |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-20 | — | — | US | disclosed |
| US-7790770-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070265325-A1 | Nitro Indazole Derivatives | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | US | disclosed |
| US-20070265325-A1 | Nitro Indazole Derivatives | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| JP-H01222078-A | PRODUCTION OF ALPHA-ARYL ACETIC ACIDS | SHONO TATSUYA | 1989-09-05 | — | — | JP | disclosed |
| US-4601797-A | Electrochemical carboxylation of p-isobutylacetophenone and other aryl ketones | MONSANTO COMPANY (US) | 1986-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | CYP3A4 537/4885ALDH1A1 2353/4885CYP19A1 291/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | CYP3A4 537/4885ALDH1A1 2353/4885CYP19A1 291/4885 |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | CYP3A4 537/4885ALDH1A1 2353/4885CYP19A1 291/4885 |
| US-20070265325-A1 | Nitro Indazole Derivatives | NOS3, CYP3A43, NOS2 | CYP3A4 4/4885ALDH1A1 490/4885CYP19A1 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.